Dragonfly Therapeutics

Dragonfly Therapeutics

  • Founded: 2015
  • Location: Waltham, MA
  • Employee range: 50 - 200
  • Clinical stage: Clin1/Clin2
  • Therapy area: Solid tumors
  • Drug types: ONC
  • Lead product: DF1001
  • Product link: https://www.dragonflytx.com/pipeline
  • Funding: 100-500M



job board

Short description:

Immuno-oncology Drugs

Drug notes:

DF6002 Clin1 solid tumors; DF9001 Clin1 solid tumors; DF2001 Clin1 leukemia (partner: BMS); DF3001 Clin1 multiple myeloma (partner: BMS); 13+ additional programs RD/Clin0 oncology, undisclosed

Long description:

Dragonfly Therapeutics is harnessing the innate immune system to develop novel immunotherapies to treat disease. Natural killer cells (NK) are employed in the body to recognise and kill cancer cells. Dragonfly is using their two proprietary platforms to create a portfolio of drugs that can activate and boost NK cell activity for therapeutic use. The first is TriNKETTM, tri-specific NK cell engagers that can trigger the cell's activity against cancer cells. The second is CYTOKINEs which fuel the NK cells activity. Dragonfly currently has six drugs in clinical trials, with their lead candidate, DF1001, in Phase 2 for patients with advanced solid tumors.


Dragonfly Therapeutics
Principal Scientist, Protein Analytics
Waltham, Massachusetts, Stati Uniti d'America|18 days ago
Dragonfly Therapeutics
Principal Scientist, Protein Analytics
Boston|18 days ago
Dragonfly Therapeutics
Senior Director, Neurobiology
Waltham, Massachusetts, Stati Uniti d'America|31 days ago
Dragonfly Therapeutics
Senior Director, Neurobiology
Boston|31 days ago
Dragonfly Therapeutics
Principal Associate Scientist/Senior Principal Ass...
Waltham, MA|50 days ago
Dragonfly Therapeutics
Waltham, MA|60 days ago

© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com